Expression of nucleic acid-sensing Toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated response

International Journal of Cancer

Volumn 136, Issue 10, 2015, Pages 2402-2408

  Scott, Mark E ^a   Ma, Yifei ^a   Farhat, Sepideh ^a   Moscicki, Anna Barbara ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cell mediated immunity; cohort study; human papillomavirus infection; Toll like receptors; women

Indexed keywords

MESSENGER RNA; PROTEIN E6; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN E7; REPRESSOR PROTEIN;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; DRINKING BEHAVIOR; FEMALE; GENOTYPING TECHNIQUE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; INTERFERON GAMMA RELEASE ASSAY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MENSTRUATION; MONOCYTE; ORAL CONTRACEPTIVE USE; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SMOKING; SURVIVAL TIME; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL LAVAGE; VIRAL CLEARANCE; ADOLESCENT; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PROPORTIONAL HAZARDS MODEL; TIME FACTOR; VAGINA SMEAR; VIROLOGY; YOUNG ADULT;

ADAPTIVE IMMUNITY; ADOLESCENT; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNITY, INNATE; LONGITUDINAL STUDIES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PROPORTIONAL HAZARDS MODELS; REPRESSOR PROTEINS; TIME FACTORS; TOLL-LIKE RECEPTORS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84924311177     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29283     Document Type: Article

References (44)

1. Clifford G, Franceschi S, Diaz M, et al. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006; 24 (Suppl 3): S26-S34.
2. Muñoz N, Bosch FX, de Sanjosé S, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
3. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 76-84.
4. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
5. Takeuchi O, Akira S,. Recognition of viruses by innate immunity. Immunol Rev 2007; 220: 214-24.
6. Daud II, Scott ME, Ma Y, et al. Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int J Cancer 2011; 128: 879-86.
7. Iwasaki A, Medzhitov R,. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-95.
8. Farhat S, Nakagawa M, Moscicki A-B,. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by IFN gamma ELISpot in women with cleared or persistent HPV infection. Int J Gynecol Cancer 2009; 19: 508-12.
9. Scott ME, Ma Y, Farhat S, et al. Covariates of cervical cytokine mRNA expression by real-time PCR in adolescents and young women: effects of Chlamydia trachomatis infection, hormonal contraception, and smoking. J Clin Immunol 2006; 26: 222-32.
10. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38: 357-61.
11. Gravitt PE, Peyton CL, Apple RJ, et al. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998; 36: 3020-7.
12. Bookout AL, Cummins CL, Mangelsdorf DJ, et al. High-throughput real-time quantitative reverse transcription PCR. In:, Ausubel FM, Brent R, Kingston RE, Moore DD, et al., eds. Current protocols in molecular biology. Hoboken, NJ: John Wiley & Sons, Inc., 2006. 15.8.1-15.8.28.
13. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3:research0034.1-0034.12.
14. Daud II, Scott ME,. Validation of reference genes in cervical cell samples from human papillomavirus-infected and -uninfected women for quantitative reverse transcription-PCR assays. Clin Vaccine Immunol 2008; 15: 1369-73.
15. Lieberman JA, Moscicki A-B, Sumerel JL, et al. Determination of cytokine protein levels in cervical mucus samples from young women by a multiplex immunoassay method and assessment of correlates. Clin Vaccine Immunol 2008; 15: 49-54.
16. Arpaia N, Barton GM,. Toll-like receptors: key players in antiviral immunity. Curr Opin Virol 2011; 1: 447-54.
17. Barbalat R, Ewald SE, Mouchess ML, et al. Nucleic acid recognition by the innate immune system. Annu Rev Immunol 2011; 29: 185-214.
18. Krieg AM,. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-60.
19. Stanley MA,. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002; 27: 571-7.
20. van Poelgeest MIE, van Seters M, van Beurden M, et al. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 2005; 11: 5273-80.
21. Chuang C-M, Monie A, Hung C-F, et al. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J Biomed Sci 2010; 17: 32.
22. Tabeta K, Georgel P, Janssen E, et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 2004; 101: 3516-21.
23. Guo Y, Audry M, Ciancanelli M, et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J Exp Med 2011; 208: 2083-98.
24. Zhang S-Y, Jouanguy E, Ugolini S, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007; 317: 1522-7.
25. Weber F, Wagner V, Rasmussen SB, et al. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol 2006; 80: 5059-64.
26. Fathallah I, Parroche P, Gruffat H, et al. EBV latent membrane protein 1 is a negative regulator of TLR9. J Immunol 2010; 185: 6439-47.
27. Hasan UA, Bates E, Takeshita F, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007; 178: 3186-97.
28. Hasan UA, Zannetti C, Parroche P, et al. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med 2013; 210: 1369-87.
29. Reiser J, Hurst J, Voges M, et al. High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol 2011; 85: 11372-80.
30. Vincent IE, Zannetti C, Lucifora J, et al. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One 2011; 6: e26315.
31. Maldonado L, Teague JE, Morrow MP, et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med 2014; 6: 221ra13.
32. Lee HK, Iwasaki A,. Innate control of adaptive immunity: dendritic cells and beyond. Semin Immunol 2007; 19: 48-55.
33. Reynolds JM, Dong C,. Toll-like receptor regulation of effector T lymphocyte function. Trends Immunol 2013; 34: 511-19.
34. Meyer T, Oberg H-H, Peters C, et al. Poly(I:C) costimulation induces a stronger antiviral chemokine and granzyme B release in human CD4 T cells than CD28 costimulation. J Leukoc Biol 2012; 92: 765-74.
35. + T cells. J Immunol 2005; 175: 1551-7.
36. + T lymphocytes express TLR3 as a functional coreceptor. J Immunol 2006; 177: 8708-13.
37. Bendigs S, Salzer U, Lipford GB, et al. CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells. Eur J Immunol 1999; 29: 1209-18.
38. + T cells through a TLR9- and MyD88-independent mechanism. J Immunol 2011; 187: 3033-43.
39. Nakagawa M, Stites DP, Palefsky JM, et al. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses. Clin Diagn Lab Immunol 1999; 6: 494-8.
40. Schulz O, Diebold SS, Chen M, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005; 433: 887-92.
41. Johansson EL, Rudin A, Wassén L, et al. Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunology 1999; 96: 272-7.
42. Pudney J, Quayle AJ, Anderson DJ,. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 2005; 73: 1253-63.
43. Galluzzi L, Vacchelli E, Eggermont A, et al. Trial watch: experimental toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1: 699-716.
44. Vacchelli E, Galluzzi L, Eggermont A, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1: 894-907.